$Intravesical electromotive botulinum toxin-A administration: Will it be the standard treatment for refractory neurogenic detrusor overactivity?$

Intravesical electromotive botulinum toxin-A administration: Will it be the standard treatment for refractory neurogenic detrusor overactivity?

Bibliographic Details
Main Authors:	Neeraj Kumar Goyal, Rahul Yadav, Apul Goel
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2011-01-01
Series:	Indian Journal of Urology
Online Access:	http://www.indianjurol.com/article.asp?issn=0970-1591;year=2011;volume=27;issue=2;spage=296;epage=297;aulast=Goyal

Similar Items

Efficacy of botulinum toxin in a patient with neurogenic detrusor overactivity
by: S. S. Nikitin, et al.
Published: (2022-09-01)

Effect of botulinum toxin type A on idiopathic and neurogenic detrusor overactivity
by: Jurij Leskovar, et al.
Published: (2010-06-01)

Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients
by: S. Deffontaines-Rufin, et al.
Published: (2011-10-01)

Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury
by: Giuseppe Lombardi, et al.

The Botulinum Treatment of Neurogenic Detrusor Overactivity: The Double-Face of the Neurotoxin
by: Chiara Traini, et al.
Published: (2019-10-01)

Re: Failure of Botulinum Toxin Injection for Neurogenic Detrusor Overactivity: Switch of Toxin Versus Second Injection of the Same Toxin
by: Lokman İrkilata
Published: (2015-12-01)

Editorial Comment: Solifenacin treatment after intradetrusor injections with botulinum toxin in patients with neurogenic detrusor overactivity
by: Marcio Augusto Averbeck
Published: (2022-11-01)

Efficacy of Intravesical Botulinum Toxin A Injection in the Treatment of Refractory Overactive Bladder in Children
by: Yu-Hua Fan, et al.
Published: (2023-03-01)

Long term safety outcomes and continuation rates of repeated Intravesical Botulinum Toxin A injections for Detrusor Overactivity: 16 year’s experience of a Tertiary Centre in the UK
by: R. Mohamed-Ahmed, et al.
Published: (2024-03-01)

Efficacy and Safety of Low-Dose Intravesical OnabotulinumtoxinA Injections in Female Patients With Detrusor Overactivity With Detrusor Underactivity
by: Hyun Seok Na, et al.
Published: (2024-03-01)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
by: Yuan-Hong Jiang, et al.
Published: (2023-01-01)

Is there any Relationship Between Bladder Trabeculation and Efficacy and Safety of Intravesical Botulinum Toxin A Injection in Refractory Idiopathic Overactive Bladder Women?
by: Mahtab Zargham, et al.
Published: (2017-01-01)

Oxybutynin and tolterodine for treatment of neurogenic detrusor overactivity: a pharmacoeconomic evaluation in the Brazilian context
by: Rodrigo Silva Suguino, et al.
Published: (2012-06-01)

Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder—Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes
by: Yin-Chien Ou, et al.
Published: (2023-01-01)

Long-term follow-up of intravesical abobotulinumtoxinA (Dysport®) injections in women with idiopathic detrusor overactivity
by: Mohammad Sajjad Rahnama'i, et al.
Published: (2024-01-01)

Editorial Comment: Long-term outcomes and risks factors for failure of intradetrusor onabotulinumtoxin A injections for the treatment of refractory neurogenic detrusor overactivity
by: Marcio Augusto Averbeck
Published: (2021-02-01)

Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity
by: Christina L Fontaine, et al.
Published: (2017-01-01)

Molecular Mechanism Operating in Animal Models of Neurogenic Detrusor Overactivity: A Systematic Review Focusing on Bladder Dysfunction of Neurogenic Origin
by: Ana Ferreira, et al.
Published: (2023-02-01)

Investigating Urine Biomarkers in Detrusor Underactivity and Detrusor Overactivity with Detrusor Underactivity Patients
by: Yuan-Hong Jiang, et al.
Published: (2023-04-01)

Botulinum toxin A for the Treatment of Overactive Bladder
by: Po-Fan Hsieh, et al.
Published: (2016-02-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

Botulinum Toxin Injection for Medically Refractory Neurogenic Bladder in Children: A Systematic Review
by: Shu-Yu Wu, et al.
Published: (2021-06-01)

BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study
by: Jacquie Maignel, et al.
Published: (2022-01-01)

Short-term outcome of onabotulinumtoxin A injection for the treatment of refractory idiopathic detrusor overactivity
by: Gamal E A. Abourjila, et al.
Published: (2020-01-01)

Percutaneous tibial nerve stimulation in the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: a historically controlled study
by: Marco Carilli, et al.
Published: (2023-05-01)

Re: The Clinical and Urodynamic Results of Percutaneous Posterior Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in Patients with Parkinson’s Disease
by: Lokman İrkilata
Published: (2015-12-01)

OBJECTIVE PARAMETERS TO DESCRIBE DETRUSOR OVERACTIVITY PATTERS
by: T van Steenbergen, et al.
Published: (2023-09-01)

Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
by: Tao Cheng, et al.
Published: (2016-01-01)

Botulinum Toxin A Injection for Autonomic Dysreflexia—Detrusor Injection or Urethral Sphincter Injection?
by: Po-Ming Chow, et al.
Published: (2023-01-01)

Efficacy, according to urodynamics, of OnabotulinumtoxinA compared with antimuscarinic drugs, for neurogenic detrusor overactivity: a systematic review and network meta-analysis
by: Rui Xu, et al.
Published: (2022-10-01)

Functional Polymorphism in the <i>ADRB3</i> Gene, Encoding the Beta-3 Adrenergic Receptor, and Response to Intra-Detrusor Injection of Botulinum Toxin-A in Women with Overactive Bladder
by: Sylwester Michał Ciećwież, et al.
Published: (2022-12-01)

Effectiveness and Safety of Intradetrusor OnabotulinumtoxinA Injection for Neurogenic Detrusor Overactivity and Overactive Bladder Patients in Taiwan—A Phase IV Prospective, Interventional, Multiple-Center Study (Restore Study)
by: Chung-Cheng Wang, et al.
Published: (2021-12-01)

Successful treatment of post COVID-19 neurogenic dysphagia with botulinum toxin
by: Riccardo Canta, et al.
Published: (2023-11-01)

Increased detrusor collagen is associated with detrusor overactivity and decreased bladder compliance in men with benign prostatic obstruction
by: Carlos H.S. Bellucci, et al.
Published: (2017-06-01)

Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements
by: Aida Javan Balegh Marand, et al.
Published: (2023-05-01)

Urinary ATP may be a dynamic biomarker of detrusor overactivity in women with overactive bladder syndrome.
by: Miguel Silva-Ramos, et al.
Published: (2013-01-01)

Development of Neurogenic Detrusor Overactivity after Thoracic Spinal Cord Injury Is Accompanied by Time-Dependent Changes in Lumbosacral Expression of Axonal Growth Regulators
by: Sílvia Sousa Chambel, et al.
Published: (2022-08-01)

Quality of Life in Female Patients with Overactive Bladder after Botulinum Toxin Treatment
by: Agnieszka A. Licow-Kamińska, et al.
Published: (2023-12-01)

Role of percutaneous tibial nerve stimulation in the management of the detrusor overactivity
by: Emad K El Tair, et al.
Published: (2022-01-01)

Coexistent Detrusor Overactivity-Underactivity in Patients with Pelvic Floor Disorders
by: Matteo Frigerio, et al.
Published: (2022-09-01)